Physician profile
Lari Johnson
NPI 1770021750
$1,128.87
in general payments reported to CMS, 2019-2025
15 companies · $21.75 in 2025
The $21.75 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $510 · 2023: $422 · 2024: $58.54 · 2025: $21.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.38 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.89 | 2021-2023 | |
| Novo Nordisk INC | $196.58 | 2022-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $61.57 | 2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $60.89 | 2022 | |
| Lilly USA, LLC | $55.20 | 2021-2023 | Mounjaro, Trulicity |
| Abbott Laboratories | $52.30 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $35.09 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.25 | 2022 | |
| Daiichi Sankyo INC. | $22.88 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.30 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $15.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lari Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.